BioSpace News Archive

Pictured: Close-up of a skin lesion in a patient w

Acelyrin’s Lead Asset Izokibep Fails in Late-Stage Hidradenitis Suppurativa Trial

Following a $540 million IPO in May, Acelyrin’s lead candidate izokibep failed to meet the primary endpoint in a Phase IIb/III study of patients with the chronic inflammatory skin condition.

September 12, 2023

·

2 min read

·

Tristan Manalac

Pictured: Novartis headquarters in Basel, Switzerl

Business

Sandoz to Commercialize Samsung Bioepis’ Biosimilar to J&J’s Stelara

As the Novartis generics and biosimilars division nears its spin-off, Sandoz has signed a commercialization agreement with Samsung Bioepis, gaining rights to the latter’s Stelara biosimilar.

September 12, 2023

·

2 min read

·

Tristan Manalac

Pictured: Illustration depicting large layoffs/iSt

Business

2seventy to Lay Off 40% of Workforce, CEO to Depart in Reorganization

Citing a challenging macro environment, 2seventy bio is launching a sweeping strategic reorganization that will see 40% of its staff laid off and CEO Nick Leschly stepping down.

September 12, 2023

·

3 min read

·

Tristan Manalac

Business people networking/iStock, Hero Images

Biopharma Career Fairs Make a Powerful Comeback

In-person events have seen a flood of demand from students who want to meet biopharma employers personally, find employers in their area and scope out the industry scene.

September 12, 2023

·

3 min read

·

Andy Gooding-Call

U.S. and U.K. flags linked_Oleksii Liskonih, iStoc

Opinion: Building a Global Presence on Both Sides of the Pond

Vaccitech recently expanded from the U.K. to the U.S. CEO Bill Enright explains why.

September 12, 2023

·

4 min read

·

William “Bill” Enright

FDA Headquarters_Grandbrothers/Adobe Stock

Drug Development

FDA Questions Efficacy of Alnylam’s Drug in ATTR-CM Ahead of Adcomm Meeting

The agency’s briefing document found Phase III results investigating patisiran’s effects versus placebo were “small, of questionable clinical meaningfulness, and may not be detectable by patients.”

September 12, 2023

·

2 min read

·

Connor Lynch

Pictured: Money growth/iStock, RomoloTavani

Rome Secures J&J, BMS Investment to Boost Series B Total to $149M

A $72 million Series B extension includes new investors Johnson & Johnson and Bristol Myers Squibb to take Rome Therapeutics’ lead asset through to Phase I studies in autoimmune disease.

September 12, 2023

·

2 min read

·

Kate Goodwin

Business

Confo Therapeutics Appoints Stephen Dowd as Chief Business Officer

Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors, announced the appointment of Stephen Dowd, PhD, MBA, to its executive team as Chief Business Officer.

September 12, 2023

·

2 min read

Business

CancerX Announces Steering Committee and Strategic Priorities

CancerX, the public-private partnership that launched in March of this year to harness the power of innovation to help achieve the goals of the Cancer Moonshot, announced its inaugural steering committee and strategic priorities.

September 12, 2023

·

6 min read

Biotech Beach

Actio Biosciences Announces $55 Million Series A Financing to Advance Precision Medicine Approach for Rare and Common Diseases

Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, announced the completion of a $55 million Series A financing.

September 12, 2023

·

6 min read